Lomotil and Gastrointestinal inflammation - a phase IV clinical study of FDA data

Summary:

Gastrointestinal inflammation is reported as a side effect among people who take Lomotil (atropine sulfate; diphenoxylate hydrochloride), especially for people who are female, 60+ old, also take Humira, and have Immunodeficiency common variable.

The phase IV clinical study analyzes which people have Gastrointestinal inflammation when taking Lomotil. It is created by eHealthMe based on reports of 18,891 people who have side effects when taking Lomotil from the FDA, and is updated regularly.

What is Lomotil?

Lomotil has active ingredients of atropine sulfate; diphenoxylate hydrochloride. It is often used in diarrhea. eHealthMe is studying from 19,184 Lomotil users. Check the latest studies of Lomotil.

What is Gastrointestinal inflammation?

Gastrointestinal inflammation (inflammation of stomach and intestine) is found to be associated with 541 drugs and 548 conditions by eHealthMe. Check the latest studies of Gastrointestinal inflammation.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

18,891 people reported to have side effects when taking Lomotil.
Among them, 38 people (0.2%) have Gastrointestinal inflammation.

Could Lomotil cause Gastrointestinal inflammation?

Among these 38 people:

What is the gender of people who have Gastrointestinal inflammation when taking Lomotil? *

female: 55.26 %
male: 44.74 %

What is the age of people who have Gastrointestinal inflammation when taking Lomotil? *

What are other drugs people take besides Lomotil? *

What are other side effects people have besides Gastrointestinal inflammation? *

Nausea (feeling of having an urge to vomit): 14 people, 36.84%
Headache (pain in head): 10 people, 26.32%
Fatigue (feeling of tiredness): 9 people, 23.68%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 9 people, 23.68%
Pain: 8 people, 21.05%
Abdominal Pain: 8 people, 21.05%
Dizziness: 7 people, 18.42%
Stress And Anxiety: 7 people, 18.42%
Urinary Tract Infection: 7 people, 18.42%
Colitis (inflammation of colon): 7 people, 18.42%

What are the existing conditions these people have? *

Immunodeficiency Common Variable: 5 people, 13.16%
High Blood Pressure: 4 people, 10.53%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 4 people, 10.53%
Multiple Myeloma (cancer of the plasma cells): 3 people, 7.89%
Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 2 people, 5.26%
Brain Neoplasm (tumour of brain): 2 people, 5.26%
Colitis Microscopic (inflammation of colon with diarrhoea and abdominal cramps): 2 people, 5.26%
Dry Eyes (lack of adequate tears): 2 people, 5.26%
Fibromyalgia (a long-term condition which causes pain all over the body): 2 people, 5.26%
Gastric Disorder (disease of stomach): 2 people, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Lomotil and have Gastrointestinal inflammation?

- Check whether Gastrointestinal inflammation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lomotil:

Lomotil (19,184 reports)

Gastrointestinal inflammation treatments and more:

Gastrointestinal inflammation (9,479 reports)

How severe was Gastrointestinal inflammation and when was it recovered:

Gastrointestinal inflammation in Lomotil

Expand to all the drugs that have ingredients of atropine sulfate; diphenoxylate hydrochloride:

Gastrointestinal inflammation and drugs with ingredients of atropine sulfate; diphenoxylate hydrochloride

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lomotil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Gastrointestinal inflammation:

Gastrointestinal inflammation (541 drugs)

Browse all the conditions that are associated with Gastrointestinal inflammation:

Gastrointestinal inflammation (548 conditions)

Related publications that referenced our studies

Schwerd T, Pandey S, Yang HT, Bagola K, Jameson E, Jung J, Lachmann RH, Shah N, Patel SY, Booth C, Runz H, "Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann–Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn9s disease", Gut, 2016 Mar .
Schwerd T, Pandey S, Yang HT, Bagola K, Jameson E, Jung J, Lachmann RH, Shah N, Patel SY, Booth C, Runz H, "Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann–Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn9s disease", Gut, 2016 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on atropine sulfate; diphenoxylate hydrochloride (the active ingredients of Lomotil) and Lomotil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.